Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 76 Shares of Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 76 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of $183.70, for a total value of $13,961.20. Following the completion of the transaction, the executive vice president directly owned 19,644 shares in the company, valued at $3,608,602.80. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Wednesday, August 26th, Michael Feld sold 165 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $188.49, for a total value of $31,100.85.
• On Monday, July 27th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $157.13, for a total value of $11,784.75.

Becton, Dickinson and Company Price Performance

Shares of BDX stock traded down $1.80 during trading hours on Tuesday, hitting $182.03. 1,528,588 shares of the company’s stock were exchanged, compared to its average volume of 1,722,243. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The stock has a market cap of $50.16 billion, a price-to-earnings ratio of 54.83, a price-to-earnings-growth ratio of 12.96 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock’s 50-day moving average is $179.26 and its 200-day moving average is $161.33.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Institutional Trading of Becton, Dickinson and Company

A number of large investors have recently made changes to their positions in the company. Auto Owners Insurance Co lifted its holdings in Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after acquiring an additional 40,528,680 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $3,721,533,000. State Street Corp lifted its holdings in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after purchasing an additional 1,177,256 shares in the last quarter. First Eagle Investment Management LLC increased its stake in Becton, Dickinson and Company by 15.8% during the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Finally, Norges Bank acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth approximately $734,321,000. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on BDX shares. Citigroup restated a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Jefferies Financial Group restated a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. TD Cowen upped their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $187.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.